Domperidone for Anorexia Refeeding: Limited Evidence and Not Recommended as Standard Practice
Domperidone is not indicated as a standard treatment for anorexia nervosa refeeding, though it may be considered in select cases where delayed gastric emptying causes severe early satiety or bloating that impedes nutritional rehabilitation. The evidence base is extremely limited, consisting primarily of small case reports from the 1980s, and domperidone is not FDA-approved for human use in the United States 1.
Clinical Context and Evidence
Historical Use in Anorexia Nervosa
The rationale for domperidone in anorexia stems from observations that delayed gastric emptying is a frequent feature in anorexia nervosa 2. Early research demonstrated:
- In one study of 30 patients with presumed anorexia nervosa, 13 of 16 patients tested had markedly delayed gastric emptying (half-emptying times 97-330 minutes vs. 21-119 minutes in controls) 2
- Domperidone 10 mg IV significantly shortened gastric emptying times in these patients (p < 0.01) 2
- Individual case reports showed improvement in both subjective satiety ratings and objective gastric emptying measures 3
Current Guideline Perspective
The 2017 ESPEN guidelines on cancer patients provide the most relevant contemporary guidance, noting that prokinetic agents like domperidone may be considered for early satiety after diagnosing and treating constipation, but clinicians must be aware of cardiac rhythm adverse effects 4. This is a weak recommendation with moderate evidence 4.
The 2025 AGA gastroparesis guidelines explicitly recommend against domperidone as first-line treatment (conditional recommendation, very low quality evidence) 1.
Practical Considerations for Anorexia Refeeding
When to Consider (Rarely)
Domperidone might be considered only when:
- Severe early satiety or bloating significantly impedes oral refeeding progress
- Constipation has been adequately addressed first 4
- Standard behavioral refeeding protocols are insufficient
- Patient has failed or cannot tolerate metoclopramide due to neurologic side effects 1
Critical Safety Requirements
Before initiating domperidone (if available):
- Obtain baseline ECG to measure QTc interval 1
- Check serum potassium and magnesium (critical in malnourished patients) 1
- Monitor these parameters throughout treatment 1
- Be aware that oral domperidone at therapeutic doses carries low but real risk of QT prolongation and torsade de pointes 4
Regulatory and Availability Issues
Domperidone is not FDA-approved for human use in the United States 1. Prescription requires:
- An expanded access investigational new drug (IND) application from the FDA 1
- As of 2025, the current supplier is exiting the business, making access increasingly difficult 1
Recommended Approach Instead
For anorexia nervosa refeeding with gastroparesis symptoms:
Prioritize structured behavioral refeeding protocols - these are the cornerstone of treatment 5, 6
Address mechanical factors first:
- Treat constipation aggressively
- Use small, frequent meals with low-fat, low-residue content
- Consider liquid nutrition if solid food tolerance is poor
If prokinetic needed, metoclopramide is better studied - though it carries CNS side effects including extrapyramidal symptoms and tardive dyskinesia risk 4
Monitor renal function during refeeding - 33% of hospitalized patients with anorexia have baseline eGFR <90, which improves with refeeding 7
Assess efficacy at 4-8 weeks if domperidone is used 1
Key Pitfalls
- Do not use domperidone as routine prophylaxis during refeeding - the evidence doesn't support this
- Do not overlook cardiac monitoring - malnourished patients are already at risk for arrhythmias
- Do not assume gastroparesis symptoms indicate need for prokinetics - they often resolve with nutritional rehabilitation alone 2
- Do not confuse domperidone's limited evidence in anorexia with its broader (though still controversial) use in gastroparesis 1, 8
The evidence for domperidone in anorexia refeeding consists of decades-old case reports 2, 3, 8. Modern eating disorder treatment emphasizes structured behavioral approaches to refeeding 9, 5, 6, with pharmacologic interventions reserved for specific complications rather than routine use.